We are pleased to introduce AATHEN - the Advanced Angiotensin Therapeutics Network - a new multi-Centre, tri-Faculty UBC Research Excellence cluster.
Angiotensin receptor blockers (ARBs), such as losartan, are a class of small molecules developed in the mid-90's to treat hypertension.
Nowadays considered 'wonder medications' that should be used prophylactically like aspirin and statins, ARBs have documented therapeutic properties in a growing list of indications not linked to hypertension, such as cancer, diabetes, Alzheimer's disease, aortic root disease, chronic lung diseases, inflammation, muscular dystrophy, sleep apnea and COVID-19, to name a few.
We have created AATHEN to facilitate collaborations between Investigators to study, optimize and evaluate ARBs in non-blood pressure-related diseases. We also support the identification of novel non-blood pressure biomarkers of ARB activity and help screening and development of new ARB-derived small molecules specifically designed for these new indications.
Welcome to AATHEN and enjoy our new website!